SCHEMBL20093365

SCHEMBL20093365

CC(C)NC(=O)/C=C/CN1CCN(C2CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 6/20 0.43
HTT P42858 1/20 0.38
GAA P10253 3/20 0.38
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.34
ELANE P08246 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP2C19 P33261 1/20 0.33
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.32
CHRM5 P08912 2/20 0.32
CHRM1 P11229 2/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16665113 0.85 SIGMAR1 (0.38) SIGMAR1HTTALDH1A1POLBEGFR
SCHEMBL19040084 0.83 KDM4E (0.36) SIGMAR1HTTALDH1A1ELANEMEN1
SCHEMBL16665575 0.83 GAA (0.46) GAAALDH1A1POLBMAPK1ELANE
SCHEMBL19010127 0.83 ALDH1A1 (0.46) SIGMAR1GAAALDH1A1MAPK1ELANE
SCHEMBL26650941 0.82 ALDH1A1 (0.40) HTTGAAALDH1A1MAPK1ELANE
SCHEMBL16665572 0.82 ALDH1A1 (0.42) SIGMAR1GAAALDH1A1MAPK1CYP2C19
SCHEMBL17339762 0.82 ALDH1A1 (0.44) GAAALDH1A1MAPK1ELANEMEN1
SCHEMBL23336316 0.81 SIGMAR1 (0.37) SIGMAR1HTTALDH1A1POLBMEN1
SCHEMBL17150483 0.79 KDM4E (0.36) SIGMAR1ALDH1A1MEN1KMT2A
SCHEMBL16665574 0.78 SMN1; SMN2 (0.46) GAAALDH1A1MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210315894-A9 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-10-14 US disclosed
US-10906889-B2 Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-02-02 US disclosed
US-20200338075-A1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-10-29 US disclosed
US-10695346-B2 4,6-pyrimidinylene derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-06-30 US disclosed
US-10342798-B2 Fused bicyclic pyrimidine derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-07-09 US disclosed
US-20190031642-A1 POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) PARAZA PHARMA, INC. (CA) 2019-01-31 US disclosed
US-20180153894-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-06-07 US disclosed
US-20180110778-A1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200338075-A1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF CDK3, CDK1, CDK14 SIGMAR1 4353/4885HTT 4195/4885GAA 4222/4885
US-10906889-B2 Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) CDK13, CDK3, CDK12 SIGMAR1 4746/4885HTT 3665/4885GAA 3616/4885
US-10695346-B2 4,6-pyrimidinylene derivatives and uses thereof CDK3, CDK1, CDK14 SIGMAR1 4353/4885HTT 4195/4885GAA 4222/4885
US-20190031642-A1 POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK13, CDK3, CDK12 SIGMAR1 4746/4885HTT 3665/4885GAA 3616/4885
US-20210315894-A9 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF CDK3, CDK1, CDK14 SIGMAR1 4353/4885HTT 4195/4885GAA 4222/4885
US-20180110778-A1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF CDKL4, CDKL5, PIP5K1A SIGMAR1 4011/4885HTT 4038/4885GAA 3551/4885
US-10342798-B2 Fused bicyclic pyrimidine derivatives and uses thereof CDK3, CDK14, CDK1 SIGMAR1 4458/4885HTT 4459/4885GAA 4047/4885
US-20180153894-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF CDK3, CDK14, CDK1 SIGMAR1 4458/4885HTT 4459/4885GAA 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.